AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01155388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron
Description: Active Comparator: Oral iron
Study NCT03312465 — intervention group
Intervention type: DEVICE
Intervention: AS Domelock System
Description: Hemi or Total Shoulder Arthroplasty
Study NCT03841825 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene instructions
Description: Oral hygiene instructions and motivation
Study NCT03841825 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral hygiene instructions
Description: Oral hygiene instructions and motivation
Study NCT03968146 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: additional Fentanyl
Description: patients will receive another dose of fentanyl 1 µg/kg 1 minute before start of skin incision.
Study NCT03968146 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Morphine
Description: After end of surgery and emergence from anesthesia, patients will receive continuous intravenous morphine with 0.03 mg/kg/hr.
Study NCT03620903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib / Bortezomib / Rituximab
Description: Induction (Rituximab / Bortezomib / Ibrutinib), Maintenance I (Ibrutinib / Rituximab), Maintenance II (Ibrutinib)
Study NCT01718236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium + sugammadex
Description: Administration of rocuronium 1 mg/kg, intubation at decrease in Single Twitch to 10% of baseline event. by the disappearance of visible spikes event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, neuromuscular blockade TOF count at 1-2.At the end of operation at PTC 1-2 sugammadex 4 mg/kg, at the TOF count 1-2, sugammadex 2 mg/kg, in the case of failure to achieve these values the anesthesiologist will wait until the minimum value of PTC 1-2 will be achieved. In can not intubate can not ventilate, and the failure of the introduction of laryngeal masks sugammadex 16mg/kg, immediately following the discovery of this fact and wait for the recovery of muscle strength. Time to recovery is recorded.
Study NCT01718236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Succinylcholine + Neostigmine
Description: 1mg/kg succinylcholine iodide, intubation after decrease in Single Twitch to 10% of baseline event. after the disappearance of visible fasciculation event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, at the moment of 20-30% of the original value of Single Twitch rocuronium 0.3 mg / kg, maintaining TOF Count at 1-2.At the end of operation at TOF Count 1-2 atropine 0.01 mg/kg and neostigmine 0.03 mg/kg. If TOF not 1-2 wait.In can not intubate can not ventilate, wait for the spontaneous recovery. Time to recovery of muscle strength is recorded.
Study NCT03968146 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: rescue Morphine
Description: Morphine IV will be given as rescue analgesia (20 µg/kg) in all study groups if VAS pain score more than 3. The total maximum hourly morphine is 0.75 mg/kg/hr.
Study NCT03968146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rescue Morphine
Description: Morphine IV will be given as rescue analgesia (20 µg/kg) in all study groups if VAS pain score more than 3. The total maximum hourly morphine is 0.75 mg/kg/hr.
Study NCT03968146 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pethidine
Description: After reaching maximum hourly morphine and the patient is still in pain, pethidine will be used as a rescue at 0.5 mg/kg.
Study NCT03968146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pethidine
Description: After reaching maximum hourly morphine and the patient is still in pain, pethidine will be used as a rescue at 0.5 mg/kg.
Study NCT03968146 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketorolac
Description: patients will receive IV ketorolac from the postoperative second day 15 mg q 6 hours, not to exceed 5 days.
Study NCT03968146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: patients will receive IV ketorolac from the postoperative second day 15 mg q 6 hours, not to exceed 5 days.
Study NCT03968146 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: patients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
Study NCT03968146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: patients will receive postoperative IV acetaminophen IV 10 mg/ kg q 6 hours
Study NCT03701503 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet with balance composition to know the effect of a meal to gut hormones in obese and non obese women
Study NCT03701503 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet with balance composition to know the effect of a meal to gut hormones in obese and non obese women
Study NCT02936895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: vitamin D at a dose of 50,000 IU per day for 2 days
Study NCT02936895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 2 days
Study NCT00631462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG101348
Description: Orally administered, once a day, for 28 days, up to 6 cycles.
Study NCT01930071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PQ Bypass Guide Wire Delivery System
Description: The PQ Bypass Guide Wire Delivery System is used to bypass lesions in the peripheral vasculature percutaneously. A guidewire is placed from the artery proximal to the lesion to the artery distal to the lesion using the vein as a conduit with the Guidewire Delivery System. Once in place, commercially available stent grafts will be placed to complete the bypass.
Study NCT04632979 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Backwards running on a Treadmil with a negative slope
Description: Running backward on a treadmill with a negative slope
Study NCT01167127 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release
Description: OXN Tablet, oral, BID, flexible dose design
Study NCT02806401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: landmark
Study NCT02806401 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: US_Ax
Study NCT02913807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Customized Jigs and Plates
Description: The titanium locking reconstruction plates will be prefabricated based on the preoperative CT scans. Prior to procedure, customized planning for osteotomies will generate the prefabricated jigs.
Study NCT02913807 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Hand Contoured Osteotomies and Reconstruction Bars
Description: This will be the traditional method of hand-conjuring the bar and bony sites.
Study NCT00118235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00118235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00118235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00118235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02570477 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: Healthy donor is screened and donates feces. It will then be diluted with sterile saline, blended and filtered. Supernatant will be infused to recipient.
Study NCT02570477 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: 125mg Vancomycin four times per day
Study NCT02702882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fenugreek Seeds Extract
Description: Furosap one caps OD
Study NCT01747694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-respiratory muscle training
Description: Patients will be taught the diaphragmatic breathing technique at the same time also will be instructed a four-item (including upper-arm weighted exercise, body side-bends, modified sit-ups, body crunching) multi-respiratory muscle training motions. To practice three times/day, three days a week lasting 12 weeks at home.
Study NCT03399214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOP Injection
Description: T1 and T2
Study NCT03776058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet
Description: Tablets for oral administration
Study NCT03776058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets for oral administration
Study NCT01293474 — intervention group
Intervention type: DEVICE
Intervention: Spectralis® SD-OCT, Heidelberg Engineering GmbH, H
Description: Measurement of the choroidal thickness with Spectralis® SD-OCT
Study NCT02523963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: family work shop
Description: 1. The family work shop has 5 courses, with 6 families in one course.~2. One course of intervention: 2-3 hours per session, one time per week, for a total of 6 sessions in 6 week periods
Study NCT00840476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg Tablets
Description: 1 x 15 mg, single-dose fasting
Study NCT00840476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mobic® 15 mg Tablets
Description: 1 x 15 mg, single-dose fasting
Study NCT00850148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anwar
Description: Anwar surgical method
Study NCT00850148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Melles
Description: Melles surgical method
Study NCT00817440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
Study NCT00817440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: 3 days of fasting and then the same as arm 1
Study NCT01112761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Each type of stimulation will be administered with a time interval of a week in between to prevent any carryover affects.
Study NCT02599558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge
Description: A capsule with a string attached with a sponge inside is swallowed. The string is held without any tension to allow the capsule to move into the stomach. The string will be held for five minutes to allow the capsule to dissolve in the stomach; a round mesh sponge about the size of a quarter is released.
Study NCT02882776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Ginger drink
Description: Ginger powder dissolved in water
Study NCT03684538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Patients will receive probiotics (Saccharomyces boulardii) one dose per day (250 mg)
Study NCT03684538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Patients will receive zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
Study NCT03684538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics & Zinc
Description: Patients will receive a combination of probiotics (Saccharomyces boulardii 250 mg) with zinc (10 mg for patients less than 6 month and 20 mg for older patients) one dose per day
Study NCT03684538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified
Study NCT03684538 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: initiation of hydration and early refeeding, in addition to the use of antimicrobials in case a pathogen was identified
Study NCT03935880 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cartiva Implant
Description: Cartiva hemiarthroplasty: The procedure starts with a small incision over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected, leaving approximately 2 mm of surrounding bone on the metatarsal head. A guide pin is placed within the metatarsal and a drill is then used to create a site for the implant. The implant is then placed using the implant introducer. The incision is then closed and a sterile dressing is placed.
Study NCT03935880 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cheilectomy
Description: Cheilectomy: A small incision is made over the top of the 1st MTP joint. The joint is exposed. Bone spurs on the metatarsal and proximal phalanx are resected. The top of the metatarsal head is then cut with a sagittal saw. Additional bone spurs are resected. The incision is closed and a sterile dressing is placed.
Study NCT02558491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Decision Support System
Description: The purpose of this study is to demonstrate the safety and feasibility of a Decision Support System aimed at reducing glucose variability in T1DM patient using an insulin pump or MDI. The system will be deployed on our portable medical application platform (DiAs) and will include the following elements:~1. An insulin pump treatment parameters optimization routine, using a month of collected CGM/insulin/meal data~2. An exercise risk warning system, capable of predicting hypoglycemia at the onset of physical activity and advising on mitigating alteration of treatment.~3. A smart bolus calculator based on CGM glucose measurements and insulin sensitivity estimation.
Study NCT02558491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: During the Control study admission, DiAs will be programmed with the home insulin dosing parameters. The study subject will use the home basal/bolus MDI or continuous subcutaneous insulin infusion (CSII) insulin regimen via the home insulin pens or pump and determine the amount of insulin to give for the entire admission per the subject's home carb counting parameters and as calculated by the DiAs meal screen.
Study NCT03523039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CytoSorb® Hemoadsorption
Description: The therapy is initiated within 6 hours from randomization and maintained for a minimum of 12 consecutive hours to a maximum of 24 consecutive hours.
Study NCT01307124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: kaletra
Description: The study participants will receive Lopinavir/ritonavir heat-stable tablet (100/25 mg or 200/50 mg) q 12 hour plus NRTIs. The other NRTIs is depend on physician discretion.~Arm 1:LPV/r Standard dose Arm 2:Low dose BW 25-35 kg 300/75 mg 200/50 mg BW >35-50 kg 400/100 mg 300/75 mg
Study NCT01307124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: kaletra
Description: The study participants will receive Lopinavir/ritonavir heat-stable tablet (100/25 mg or 200/50 mg) q 12 hour plus NRTIs. The other NRTIs is depend on physician discretion.~Arm 1:LPV/r Standard dose Arm 2:Low dose BW 25-35 kg 300/75 mg 200/50 mg BW >35-50 kg 400/100 mg 300/75 mg
Study NCT00834743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucophage® XR 750 mg Tablets
Description: 1 x 750 mg, single-dose fasting
Study NCT00834743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin ER 750 mg Tablets
Description: 1 x 750 mg, single-dose fasting
Study NCT04313751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education, Physical Activity, and Stress Management Program
Description: Twelve weekly classes for one hour focused on CVD risk factor education using the Su Corazón Su Vida curriculum and coping skills training followed by a 45 minute exercise class and 15 minute stress management session. Then they will return for one hour for continued support, a forty-five minute exercise class, and fifteen minute stress management session.
Study NCT04313751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list
Description: The wait-list control group will receive 12 weekly one hour education and coping skills training sessions followed by a 45 minute exercise class and a 15 minute stress management session.
Study NCT03730168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: circuit weight training program
Description: 30 male diabetic patients performed circuit weight training for 12 weeks
Study NCT00830349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 1 mg Tablet
Study NCT00830349 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 1 mg Tablets
Study NCT00462345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 1000 mg i.v. on Days 1 and 15
Study NCT00462345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24
Study NCT02262611 — intervention group
Intervention type: DRUG
Intervention: Micardis®
Study NCT04617288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound Therapy, SNAGs
Study NCT02391805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir
Description: Entecavir will be administered as per local labeling.
Study NCT00462345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid or NSAID
Description: ≤10 mg/day prednisone p.o., or equivalent corticosteroid, or NSAIDs p.o. from Day 1 through Week 24
Study NCT00462345 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folate
Description: ≥5 mg/week, once daily or b.i.d. from Day 1 through Week 24
Study NCT00542984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: teriparatide 20 micrograms/day subcutaneous
Study NCT00542984 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: salmon calcitonin 100 IU/day subcutaneous
Study NCT03445286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Description: Silver Diamine Fluoride (Advantage Arrest) for the experimental group
Study NCT03445286 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline for the control group
Study NCT02471963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Study NCT02471963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01430247 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Amblyopia screening
Description: Monocular vision testing at near (40cm) and distance (3m)
Study NCT00705900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCD
Description: 2 applications / day for 12 weeks
Study NCT00705900 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcipotriol
Description: 2 applications / day for 12 weeks
Study NCT03992300 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical adjustment
Description: Accuracy of the framework is checked in the patient mouth by tactile perception, screwing torque, Sheffield test and radiography.
Study NCT02391805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir will be administered as per local labeling.
Study NCT03992300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinical adjustment
Description: Accuracy of the framework is checked in the patient mouth by tactile perception, screwing torque, Sheffield test and radiography.
Study NCT00337051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: General anesthesia using Sevoflurane (inhalation) as hypnotic
Study NCT00337051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General anesthesia with propofol TCI
Study NCT03919240 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR T-cell therapy
Description: Patients enrolled will receive infusion of CD19-targeting CAR T-cells with a target dose of 5\~10×10E6/kg of recipient weight, after the preparative regimen consisted of fludarabin (30mg/m2, day -5 to -3) and cyclophosphamide (300mg/m2, day -5 to -3).
Study NCT04420793 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: 3 voice recording tasks and 1 text entry task will be performed.
Study NCT01848314 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Flowmeasurements will be performed before and after renal denervation
Study NCT01509027 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: education by DVD
Description: Information on detrimental conseqences of hyperphosphatemia is presented on DVD
Study NCT01509027 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: standard care
Study NCT01509027 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education by DVD and dietician
Description: Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
Study NCT03263806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CTFFR-Guided Group Management
Description: Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results will be communicated to the provider who will use CTFFR interpretation to guide care pathway.